Document is current

Article History

Accepted: 22 June 2025

First Online: 28 July 2025

Declarations

:

: The authors did not receive support from any organization for the submitted work.

: Becky Pennington is funded by a National Institute for Health and Care Research (NIHR) Fellowship (300160) and is a member of NICE Technology Appraisal Committee A. James Fotheringham is vice-chair of NICE Technology Appraisal Committee A. All authors were involved in the NICE Technology Appraisal of Tirzepatide for managing overweight and obesity (TA1026). Albany Chandler was involved in the NICE Technology Appraisal of Semaglutide for managing overweight and obesity (TA875). The conclusions presented within this paper are those of the authors themselves and do not necessarily represent those of NICE, the NIHR or the University of Sheffield.

: This article does not contain any studies with human participants performed by any of the authors.

: Not applicable.

: All authors provide this consent.

: All data desrcibed within the manuscript are publically available from cited sources.

: Not applicable.

: All authors contributed to the conceptualisation of the manuscript, drafted sections of text, reviewed and revised content, and approved the final version.